Consensus guidelines on the management of MNGIE have suggested considering either haematopoietic stem cell transplant (HSCT) or liver transplant as a permanent treatment option for replacing thymidine phosphorylase activity and that the decision would depend on multiple patient‐ and centre‐related factors and experience, given the high risk of morbidity and mortality especially with HSCT [161]. The gene discussed is TYMP; the disease is mitochondrial neurogastrointestinal encephalomyopathy.